Lessons learned from SITC – Part 1
Not all high TMB tumours are inflamed…
Discussing the lessons learned from preclinical research or clinical trials, while not a popular endeavour for obvious reasons, are nevertheless an important part and parcel of oncology R&D.
Sometimes we learn more from failure than we do from success.
Other times we can be inspired by some cool science which turns out to be pivotal in changing how we think about future strategies.
In a two-part series from SITC this week we are going to cover some key findings across various talks and posters, which are not simply run of the mill rehashes or perfunctory phase 1 dose escalation studies.
What lies beneath the bonnet for the curious amongst you?
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
